NASDAQ:ADAP - Adaptimmune Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.75 +0.09 (+1.93 %)
(As of 02/22/2019 12:01 PM ET)
Previous Close$4.66
Today's Range$4.72 - $4.81
52-Week Range$3.60 - $14.63
Volume1,493 shs
Average Volume213,338 shs
Market Capitalization$448.50 million
P/E Ratio-5.88
Dividend YieldN/A
Beta1.37
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients. It is developing MAGE A-10 peptide that is in Phase I/II clinical trials for the treatment of urothelial, melanoma, and head and neck cancers, as well as non-small cell lung cancer (NSCLC); MAGE-A4 to treat urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, and gastric cancers; and AFP SPEAR T-cell therapeutic candidate that is in Phase I/II clinical trials for targeting a peptide associated with hepatocellular carcinoma. Adaptimmune Therapeutics plc has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with The University of Texas MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell therapy in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a co-development and co-commercialization agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.

Receive ADAP News and Ratings via Email

Sign-up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADAP
CUSIPN/A
Phone44-12-3543-0000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$37.83 million
Book Value$2.17 per share

Profitability

Net Income$-70,130,000.00
Net Margins-139.57%

Miscellaneous

Employees371
Market Cap$448.50 million
Next Earnings Date2/27/2019 (Confirmed)
OptionableOptionable

Adaptimmune Therapeutics (NASDAQ:ADAP) Frequently Asked Questions

What is Adaptimmune Therapeutics' stock symbol?

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) posted its quarterly earnings results on Thursday, August, 2nd. The biotechnology company reported ($0.48) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.20. The biotechnology company earned $9.04 million during the quarter, compared to analysts' expectations of $7.76 million. Adaptimmune Therapeutics had a negative net margin of 139.57% and a negative return on equity of 41.63%. View Adaptimmune Therapeutics' Earnings History.

When is Adaptimmune Therapeutics' next earnings date?

Adaptimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Adaptimmune Therapeutics.

What price target have analysts set for ADAP?

5 brokerages have issued 12 month price targets for Adaptimmune Therapeutics' shares. Their predictions range from $12.00 to $20.00. On average, they expect Adaptimmune Therapeutics' share price to reach $16.00 in the next twelve months. This suggests a possible upside of 234.0% from the stock's current price. View Analyst Price Targets for Adaptimmune Therapeutics.

What is the consensus analysts' recommendation for Adaptimmune Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adaptimmune Therapeutics.

Has Adaptimmune Therapeutics been receiving favorable news coverage?

Media headlines about ADAP stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Adaptimmune Therapeutics earned a news sentiment score of 1.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the stock's share price in the near term.

Who are some of Adaptimmune Therapeutics' key competitors?

What other stocks do shareholders of Adaptimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gran Tierra Energy (GTE), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Alibaba Group (BABA) and Twitter (TWTR).

Who are Adaptimmune Therapeutics' key executives?

Adaptimmune Therapeutics' management team includes the folowing people:
  • Mr. James Julian Noble, CEO & Director (Age 60)
  • Dr. Helen Katrina Tayton-Martin, Co-Founder & Chief Bus. Officer (Age 52)
  • Mr. Adrian Rawcliffe, Chief Financial Officer (Age 47)
  • Mr. William C. Bertrand Jr., Chief Operating Officer (Age 54)
  • Mr. Sébastien Desprez, VP of Communications & Investor Relations

When did Adaptimmune Therapeutics IPO?

(ADAP) raised $150 million in an IPO on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who are Adaptimmune Therapeutics' major shareholders?

Adaptimmune Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.92%), Orbimed Advisors LLC (1.43%), BlackRock Inc. (0.91%), Foresite Capital Management II LLC (0.74%), Tekla Capital Management LLC (0.24%) and D. E. Shaw & Co. Inc. (0.23%). Company insiders that own Adaptimmune Therapeutics stock include Adrian Rawcliffe, Ali Behbahani, David M Mott, Enterprise Associates 14 New, Gwendolyn Knowlt Binder-Scholl, Lawrence M Alleva, Orbimed Advisors Llc, Peter A Thompson, Rafael Amado, Ravi Viswanathan and William C Bertrand, Jr. View Institutional Ownership Trends for Adaptimmune Therapeutics.

Which major investors are selling Adaptimmune Therapeutics stock?

ADAP stock was sold by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC, WS Management Lllp, D.A. Davidson & CO. and Weiss Multi Strategy Advisers LLC. Company insiders that have sold Adaptimmune Therapeutics company stock in the last year include Adrian Rawcliffe, Gwendolyn Knowlt Binder-Scholl, Orbimed Advisors Llc, Peter A Thompson, Rafael Amado and William C Bertrand, Jr. View Insider Buying and Selling for Adaptimmune Therapeutics.

Which major investors are buying Adaptimmune Therapeutics stock?

ADAP stock was acquired by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Baillie Gifford & Co., D. E. Shaw & Co. Inc., Foresite Capital Management II LLC, Squarepoint Ops LLC, BlackRock Inc., Bellevue Group AG and Acadian Asset Management LLC. Company insiders that have bought Adaptimmune Therapeutics stock in the last two years include Ali Behbahani, David M Mott, Enterprise Associates 14 New, Lawrence M Alleva, Orbimed Advisors Llc and Ravi Viswanathan. View Insider Buying and Selling for Adaptimmune Therapeutics.

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adaptimmune Therapeutics' stock price today?

One share of ADAP stock can currently be purchased for approximately $4.79.

How big of a company is Adaptimmune Therapeutics?

Adaptimmune Therapeutics has a market capitalization of $452.27 million and generates $37.83 million in revenue each year. The biotechnology company earns $-70,130,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Adaptimmune Therapeutics employs 371 workers across the globe.

What is Adaptimmune Therapeutics' official website?

The official website for Adaptimmune Therapeutics is http://www.adaptimmune.com.

How can I contact Adaptimmune Therapeutics?

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected]


MarketBeat Community Rating for Adaptimmune Therapeutics (NASDAQ ADAP)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  208 (Vote Underperform)
Total Votes:  422
MarketBeat's community ratings are surveys of what our community members think about Adaptimmune Therapeutics and other stocks. Vote "Outperform" if you believe ADAP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADAP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel